This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Europe's premier partnering event
November 4–6, 2024 | Stockholm, SwedenNovember 12–13, 2024 | Digital Partnering

Biotts SA


Most medications are still administered to patients with injections, yet patients are increasingly asking for more patient-friendly, non-invasive alternatives. For most pharmaceutical actives injections have always been the only possibility, but Biotts is changing this, making transdermal drug delivery a viable alternative. Biotts' unique MTC-Y transdermal carrier system allows for the transdermal delivery of small molecules, but also larger molecules like proteins and peptides, both lipophilic and hydrophilic. Biotts' unique transdermal carrier system replaces the traditional injection needle with a simple patch or an ointment, thus offering non-invasive and patient-friendly medicine alternatives. The first two products in our pipeline are an insulin patch (diabetes) and a semaglutide patch (diabetes/obesity), but the technology is universal and versatile so can be applied to many other therapies offer unlimited new opportunities for non-invasive drug administration to patients. Even though the technology can be applied in many therapeutic areas, the initial target market is diabetes and obesity. Patients using insulin or GLP-1 are increasingly asking for non-invasive alternatives to injections. Biotts is the only option for non-invasive, patient-friendly administration of larger molecules like proteins and peptides. Other companies offering transdermal delivery of larger molecules use micro-needles i.e. still invasive and very complex (expensive). Non of these competitors are working with insulin/semaglutide.